Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

t(R) appeared to provide a similar magnitude of seizure reduction versus placebo regardless of which AED was included as part of the patients' baseline treatment regimen, which included one to three concomitant AEDs:

    -- Carbamazepine (36.5 percent seizure frequency reduction with Vimpat(R)
       400 mg/day vs. 21.7 percent with placebo)
    -- Lamotrigine (33.3 percent vs. 18.3 percent)
    -- Levetiracetam (37.6 percent vs. 17.6 percent)
    -- Valproate (45.3 percent vs. 21.3 percent)
    -- Topiramate (41.4 percent vs. 28.5 percent)
    -- Oxcarbazepine (27.2 percent vs. 12.5 percent)

Similar results were seen for responder rates (patients with 50 percent or greater reduction in seizure frequency):

    -- Carbamazepine (37.4 percent responder rate with Vimpat(R) 400 mg/day
       vs. 26.4 percent placebo)
    -- Lamotrigine (34.2 percent vs. 19.0 percent)
    -- Levetiracetam (43.4 percent vs. 19.4 percent)
    -- Valproate (47.5 percent vs. 26.9 percent)
    -- Topiramate (41.9 percent vs. 25.6 percent)
    -- Oxcarbazepine (29.7 percent vs. 17.6 percent)

Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.246)

William Rosenfeld, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty, PhD

The Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, Missouri

Schwarz Biosciences Inc. (a member of the UCB Group), Raleigh, NC, USA

Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials

This pooled analysis clinical trial safety data showed Vimpat(R) to be generally well-tolerated, although 85 percent of trial participants were already taking two to three concomitant AEDs upon trial entry:

-- The most frequently reported individual treatment emergent adverse events (TEAE) occurring in greater than or equal to 10 percent of the Vimpat(
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... the last decade, the laboratory filtration market is experiencing ... acceptance of new filtration technologies in end users market. ... catalyzing the growth of laboratory filtration market. , The ... a strong CAGR during the forecast period of 2014-2019 ... 2019. The market is mainly driven by the increasing ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Inovail, successfully launches ... OmegaGen(R) in Australia and New Zealand, LAVAL, QC, ... (NASDAQ.NEPT - TSX.V.NTB) and its commercial,pharmaceutical partner Inovail Pty ... complementary medicine in Australia and New,Zealand. Neptune foresees this ...
... BASINGSTOKE, England, March 25 Shire plc,(LSE: SHP, ... preliminary results prepared under International Financial,Reporting Standards ("IFRS") ... On February 21, 2008 Shire announced its ... Notes to Editors, Shire plc, Shire,s ...
... IRVINE, Calif., March 25 Masimo (Nasdaq:,MASI), ... Motion and Low,Perfusion pulse oximetry, today announced ... manufacturer and supplier of,electrocardiographs, spirometers, patient monitors ... SET technology platform as,the foundational technology of ...
Cached Biology Technology:Neptune Technologies expands into medicinal markets in Asia Pacific 2Neptune Technologies expands into medicinal markets in Asia Pacific 3Shire plc: IFRS Results for the Year Ending December 31, 2007 2Shire plc: IFRS Results for the Year Ending December 31, 2007 3Shire plc: IFRS Results for the Year Ending December 31, 2007 4Shire plc: IFRS Results for the Year Ending December 31, 2007 5Shire plc: IFRS Results for the Year Ending December 31, 2007 6Shire plc: IFRS Results for the Year Ending December 31, 2007 7Shire plc: IFRS Results for the Year Ending December 31, 2007 8Shire plc: IFRS Results for the Year Ending December 31, 2007 9Shire plc: IFRS Results for the Year Ending December 31, 2007 10Shire plc: IFRS Results for the Year Ending December 31, 2007 11Shire plc: IFRS Results for the Year Ending December 31, 2007 12Shire plc: IFRS Results for the Year Ending December 31, 2007 13Shire plc: IFRS Results for the Year Ending December 31, 2007 14Shire plc: IFRS Results for the Year Ending December 31, 2007 15Shire plc: IFRS Results for the Year Ending December 31, 2007 16Shire plc: IFRS Results for the Year Ending December 31, 2007 17Shire plc: IFRS Results for the Year Ending December 31, 2007 18Shire plc: IFRS Results for the Year Ending December 31, 2007 19Shire plc: IFRS Results for the Year Ending December 31, 2007 20Shire plc: IFRS Results for the Year Ending December 31, 2007 21Shire plc: IFRS Results for the Year Ending December 31, 2007 22Shire plc: IFRS Results for the Year Ending December 31, 2007 23Shire plc: IFRS Results for the Year Ending December 31, 2007 24Shire plc: IFRS Results for the Year Ending December 31, 2007 25Shire plc: IFRS Results for the Year Ending December 31, 2007 26Shire plc: IFRS Results for the Year Ending December 31, 2007 27Shire plc: IFRS Results for the Year Ending December 31, 2007 28Shire plc: IFRS Results for the Year Ending December 31, 2007 29Shire plc: IFRS Results for the Year Ending December 31, 2007 30Shire plc: IFRS Results for the Year Ending December 31, 2007 31Shire plc: IFRS Results for the Year Ending December 31, 2007 32Shire plc: IFRS Results for the Year Ending December 31, 2007 33Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 2
(Date:9/30/2014)... what goes wrong with your muscles because of age, disease ... actually is. That,s where a new research report published in ... comes in. In the report, a team of ... can help scientists "see" which genes are active in an ... gene activity and that men have approximately 400 more active ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... 30, 2014 Winners of The Economist,s prestigious ... scheduled to take place at the JW Marriott Hong Kong on ... winners will share their experiences and the lessons those hold for ... proven innovation over the past decade, will be presented at a ... the summit. It will be the first time the ceremony has ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... WASHINGTON, N.C. , Oct. 21, 2013 Washington Eye Center ... Eye Care, effective immediately. The name was chosen to better reflect ... come to expect from Eastern North Carolina,s ... Eye Care will be the new name of the locations in ...
... map shows that most tropical rain falls in the Northern ... inches of rain a year, while an equal distance on ... long believed that this was a quirk of the Earth,s ... planet spins pushed tropical rain bands north of the equator. ...
... researchers used suction to learn that individual "molecular muscles" within ... may explain how cells "feel" the environment and appropriately adapt ... published online Oct. 20 in the journal Nature Materials ... are translated into internal signals. A computer model ...
Cached Biology News:Washington Eye Center is now Precision Eye Care 2Global ocean currents explain why Northern Hemisphere is the soggier one 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
... temperature control for microbiology and cell culture. ... is suitable for DASGIP bioreactors from 150 ... temperature ranges from approximately 10 °C to ... with an individual electrical heating element with ...
... gel stain is a sensitive nucleic acid ... to RNA and low background in gels, making ... polyacrylamide gels using laser scanners or standard UV ... mL unit size (S-7568) and a special packaging ...
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
Biology Products: